To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Middle East
Sponsored by Merck KGaA, Darmstadt, Germany
About this trial
Last updated 8 years ago
Study ID
Status
Type
Placebo
Accepting
Not accepting
Trial Timing
Ended 10 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Administered growth hormone via the easypod™ electromechanical device according to Summary of Product Characteristic (SmPC)
- Over the age of 2 years
- Under 18 years of age, or over 18 without fusion of growth plates
- Parent's or guardian's written informed consent, given before entering data into the observational study, with the understanding that the subject or parent/guardian may withdraw consent at any time without prejudice to future medical care. If the child is old enough to read and write, a separate assent form will be given as defined in the appropriate jurisdiction of each country
Exclusion Criteria
- Subjects taking growth hormone in whom growth plates have fused (that is, for taking growth hormone for it's metabolic effects)
- Contra-indications to SAIZEN® as defined in the SmPC
- Use of an investigational drug or participation in another interventional clinical study